phrykt

Adicet Bio, Inc. (ACET): who owns it and who trades it

As of Nov 16, 2026, ACET insiders reported 4 open-market sales worth $675K and 3 purchases worth $1.6M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was OrbiMed Advisors Israel II Ltd (10% owner), with $675K. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Adicet Bio

From the latest filings

Overall: more selling than buying. Famous investors mostly sold. Funds mostly bought. Insiders was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ACET

56 funds and institutions reported ACET shares worth $52.8M at the end of Q2 2026, about 64% of the company. The largest holder is Ra Capital Management, L.P. with 9.7%.

Funds and institutions (13F) 64%Everyone else 36%

10 largest owners, by share of the company

Ra Capital Management, L.P.9.7%
Orbimed Advisors LLC8.8%
Franklin Resources Inc6.5%
Citadel Advisors LLC4.5%
Vanguard Capital Management LLC3.6%
Adage Capital Partners Gp, L.l.c.2.9%
Renaissance Technologies LLC2.8%
Stonepine Capital Management, LLC2.6%
Alyeska Investment Group, L.P.2.1%
Schonfeld Strategic Advisors LLC2.0%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Ra Capital Management, L.P.932,6249.72%$8.1M-21%
Orbimed Advisors LLC844,7878.80%$7.3M-18%
Franklin Resources Inc626,5716.53%$5.4MNo change
Citadel Advisors LLC432,7384.51%$3.7M+13%
Vanguard Capital Management LLC343,2283.58%$3M+2%
Adage Capital Partners Gp, L.l.c.274,3752.86%$2.4MNo change
Renaissance Technologies LLC265,9452.77%$2.3M+14%
Stonepine Capital Management, LLC245,5182.56%$2.1M+11%
Alyeska Investment Group, L.P.203,7992.12%$1.8MNo change
Schonfeld Strategic Advisors LLC195,5142.04%$1.7MNew
Carlyle Group Inc.184,2951.92%$1.6MNo change
NEXTBio Capital Management LP157,8271.64%$1.4MNo change
Acadian Asset Management LLC124,8321.30%$1.1M+6%
Two Sigma Investments, LP96,8391.01%$837K+125%
Geode Capital Management, LLC95,6341.00%$827K-5%
DAFNA Capital Management LLC93,8120.98%$811KNo change
Bridgeway Capital Management, LLC85,9590.90%$743KNew
Marshall Wace, LLP79,4880.83%$687KNew
Trexquant Investment LP78,0020.81%$674K+79%
Jane Street Group, LLC70,5610.74%$610K+90%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ACET insiders reported $1.6M of open-market purchases and $675K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$1.6M
3 trades, 1 people
Sales, 12 months
$675K
4 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Apr 8, 2026
Filed Apr 9, 2026

Purchases and sales by month

$1.6M$1.6MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Apr 8, 2026OrbiMed Advisors Israel II Ltd +710% ownerSale32,523$6.29$205KForm 4
Apr 8, 2026OrbiMed Advisors Israel II Ltd +710% ownerSale40,416$6.52$264KForm 4
Apr 7, 2026OrbiMed Advisors Israel II Ltd +710% ownerSale29,319$6.53$191KForm 4
Apr 7, 2026OrbiMed Advisors Israel II Ltd +710% ownerSale2,400$6.38$15.3KForm 4
Feb 20, 2026RA Capital Healthcare Fund LP +310% ownerPurchase74,751$7.27$543KForm 4
Feb 19, 2026RA Capital Healthcare Fund LP +310% ownerPurchase74,268$7.21$535KForm 4
Feb 18, 2026RA Capital Healthcare Fund LP +310% ownerPurchase74,577$7.04$525KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
RA Capital Healthcare Fund LP10% owner$1.6M–Feb 20, 2026
OrbiMed Advisors Israel II Ltd10% owner–$675KApr 8, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ACET short interest

Low short interest. 4.9% of ACET shares are sold short: about 1 share in 20. Over the last 12 reports the number of shares short went down 22%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 459,550 ACET shares were sold short, 4.9% of the shares outstanding, down 11.9% from the report before. At the average daily volume of 178,752 shares, buying them all back would take about 2.6 trading days (days to cover).

Shares short, % of all shares

4.91%May 15Oct 306.64%

Days to cover

2.6May 15Oct 307.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026459,5504.91%-12%178,7522.6
Oct 15, 2026521,8835.57%+8%222,5952.3
Sep 30, 2026485,4665.19%+78%439,5131.1
Sep 15, 2026271,9892.91%+8%131,0752.1
Aug 31, 2026252,6632.70%-4%104,5082.4
Aug 14, 2026262,3572.80%-34%82,7573.2
Jul 31, 2026397,0534.14%+4%91,9514.3
Jul 15, 2026383,1743.99%-24%89,4054.3
Jun 30, 2026505,5805.27%+1%96,2125.2
Jun 15, 2026501,2545.22%-3%75,7386.6
May 29, 2026517,9225.40%-12%124,7484.2
May 15, 2026587,8376.13%+6%103,4575.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Adicet Bio company events

Adicet Bio filed 12 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Sep 28, 2026AnnouncementThe Company announced preliminary data from its Prula-cel Phase 1 study in patients with SLE with or without LN. The preliminary data, as well as additional corporate updates, are summarized below. Filing
  3. Sep 8, 2026AnnouncementShared information with investors. Filing
  4. Sep 1, 2026AnnouncementShared information with investors. Filing
  5. Aug 5, 2026ResultsReleased financial results. Filing
  6. Jun 18, 2026VoteReported shareholder vote results. Filing
  7. May 13, 2026ResultsReleased financial results. Filing
  8. Apr 28, 2026SharesSold new shares outside a public offering. Filing
  9. Mar 12, 2026ResultsReleased financial results. Filing
  10. Jan 7, 2026AnnouncementThe Company announced that enrollment in its prulacabtagene leucel (prula-cel, formerly ADI-001) Phase 1 program in autoimmune diseases has doubled to over 20 patients as of December 31, 2025. Filing
  11. Dec 29, 2025AnnouncementThe Company issued a press release announcing the Reverse Stock Split and other related information. Filing
  12. Dec 19, 2025VoteReported shareholder vote results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Adicet Bio financials

Famous investors that hold ACET

2 of the 50 well-known investors we track reported holding ACET in their latest 13F filing. The largest position is Ken Griffin's, worth $2M.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026280,372$2M0.0%-35%
Jim Simons · Renaissance TechnologiesQ3 2026214,841$1.5M0.0%-19%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ACET in the last 120 days.

FiledHolderFormStake
Oct 28, 2026Franklin Templeton, Inc.13G/A7.7%
Oct 28, 2026Franklin Templeton, Inc.13G/A7.7%
Oct 23, 2026Zedek Daniel Clayton13G5.4%
Oct 23, 2026Zedek Daniel Clayton13G5.4%

Questions about Adicet Bio, Inc. (ACET) stock

Who owns the most ACET stock?

The largest reported owner of Adicet Bio, Inc. (ACET) is Ra Capital Management, L.P., with 9.7% of the company. In total, 56 funds and institutions reported holding ACET at the end of Q2 2026, together about 64% of the shares. See the largest owners.

Are ACET insiders buying or selling?

In the last 12 months, ACET insiders reported 3 open-market purchases worth $1.6M and 4 sales worth $675K. The latest trade was on Apr 8, 2026. See every trade.

What is the short interest in ACET?

As of Oct 30, 2026, 459,550 ACET shares were sold short, 4.9% of the shares outstanding, down 11.9% from the report before. At the average daily volume of 178,752 shares, buying them all back would take about 2.6 trading days (days to cover). See the history.

Which famous investors hold ACET?

2 of the 50 well-known investors we track reported ACET in their latest 13F filing, including Ken Griffin, Jim Simons. The largest position is worth $2M. See all holders.

Executive pay

Adicet Bio's chief executive was paid a total of $1.5M for the year ended Dec 31, 2025, down 68% from $4.6M the year before. In the last 12 months, Adicet Bio's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$1.5MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$348KThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.